Bridge Biotherapeutics to Present Comprehensive Pipeline Updates at the 2022 BIO International Convention
Bridge Biotherapeutics to Present Comprehensive Pipeline Updates at the 2022 BIO International Convention Pavel Printsev, Bridge Biotherapeutics director of Business Development, will provide an overview of the company as well as the latest information on its clinical-stage assets:
BBT-207, also a fourth-generation EGFR TKI for non-small cell lung cancer (about to begin clinical trials) "We are delighted to be able to give an in-person presentation at this year's BIO International conference.
To learn more about the session and Bridge Biotherapeutics, please visit the events page on our website at https://bit.
Read full article at The Korea Herald